NCT03538691View on ClinicalTrials.gov

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

1,149

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

July 8, 2022

Study Completion Date

July 29, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

Brexpiprazole

Administered as tablets.

DRUG

Antidepressant therapy

"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."

Trial Locations (1)

90024

For additional information regarding sites, contact 844-687-8522, Los Angeles

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03538691 - A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder | Biotech Hunter | Biotech Hunter